The Pharmacokinetics, Safety, and Tolerance of Cefepime Administered as an Intravenous Bolus or as a Rapid Infusion

Garrelts, James C.; Wagner, David J.

doi:10.1345/aph.19067

Cited by 28 publications

(20 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Total body clearance (Cl B ) in cross-bred calves was higher than the values reported in foals and cow calves, but lesser than corresponding values in humans and dogs. The value of Cl B reported in foals (Gardner and Papich 2001), cow calves (Ismail 2005a), humans (Garrelts and Wagner 1999) and dogs (Gardner and Papich 2001) was 78, 66, 126 and 129.6 ml.kg −1 .h, respectively. A longer MRT was found in febrile calves (2.76±0.05 h) as compared to healthy ones (2.41±0.04 h).…”

Section: Discussionmentioning

confidence: 91%

Influence of E. coli lipopolysaccharide induced fever on the plasma kinetics of cefepime in cross-bred calves

Pawar

Sharma

2007

Vet Res Commun

View full text Add to dashboard Cite

The pharmacokinetic behavior of cefepime was studied in healthy and febrile cross-bred calves after single intravenous administration (10 mg/kg). The fever was induced with E. coli lipopolysaccharide (1 microg/kg, IV). The drug concentration in plasma was detected by microbiological assay method using E. coli (MTCC 739) test organism. Pharmacokinetic analysis of disposition data indicated that intravenous administration data were best described by 2 compartment open model. At 1 min the concentration of cefepime in healthy and febrile animals were 55.3 +/- 0.54 microg/ml and 50.0 +/- 0.48 microg/ml, respectively and drug was detected up to 12 h. The elimination half-life of cefepime was increased from 1.26 +/- 0.01 h in healthy animals to 1.62 +/- 0.09 h in febrile animals. Drug distribution was altered by fever as febrile animals showed volume of distribution (0.27 +/- 0.02 L/kg) higher than normal animal (0.19 +/- 0.01 L/kg). Total body clearances in healthy and febrile animals were 104.4 +/- 2.70 and 114.2 +/- 1.20 ml/kg/h, respectively. To maintain minimum therapeutic concentration of 1 mug/ml, a satisfactory dosage regimen of cefepime in healthy and febrile cross-bred calves would be 15.5 mg/kg and 8.2 mg/kg body weight, respectively, to be repeated at 8 h intervals. The T>MIC values (8 h) of cefepime suggested that this agent is clinically effective in the treatment of various infections.

show abstract

Section: Discussionmentioning

confidence: 91%

Influence of E. coli lipopolysaccharide induced fever on the plasma kinetics of cefepime in cross-bred calves

Pawar

Sharma

2007

Vet Res Commun

View full text Add to dashboard Cite

show abstract

“…, 1987), rats (Brindley et al. , 1991), humans (Garrelts & Wagner, 1999), dogs (Stampley et al. , 1992), horses (Guglick et al.…”

Section: Pharmacokinetic Parameters Of Cefepime Equivalent In Buffalmentioning

confidence: 99%

Pharmacokinetic disposition and bioavailability of cefepime in buffalo calves

Joshi

Sharma

2007

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

“…Moreover, its claimed limited potential to induce resistance should result in fewer secondary infections and better outcomes [29,41] . Numerous clinical trials on cefepime for the treatment of various infections have generally shown its comparable or superior efficacy against comparators, including third-generation cephalosporin and other β -lactams [42][43][44][45][46][47][48][51][52][53][54][55][56][57][58][59][60][61][62][63][64][67][68][69][70][71][72][73][74][75][76][77][78][79][80][81]84,[87][88][89][90]99] . Results of these studies indicated cefepime as safe and well-tolerated in both adults and children.…”

Section: Discussionmentioning

confidence: 99%

“…The pharmacokinetic properties of intravenous and intramuscular cefepime have been thoroughly investigated, and have been widely reviewed previously [31,45,46] . Studies comparing continuous infusion and intermittent bolus dosing suggest that the two administration routes are at least equally clinically efficacious, even if pharmacodynamic and pharmacoeconomic adavantages make continuous infusion the preferred method for cefepime administration [47] .…”

Section: Pharmacokineticsmentioning

confidence: 99%

The safety of cefepime in the treatment of infection

Drago

Vecchi

2008

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Background : Cefepime is a fourth-generation cephalosporin usually reserved for treating severe nosocomial pneumonia, as well as empirical treatment of febrile neutropenia, uncomplicated and complicated urinary tract infections, uncomplicated skin and skin structure infections, and complicated intra-abdominal infections. Objective : Since reports of neurotoxic effects and of an all-cause mortality higher with cefepime than with comparators have created some concerns regarding its safety, this paper reviews data available in the PubMed database up to December 2007 on cefepime safety. Methods : Literature data from PubMed obtained by combining cefepime and safety, or cefepime and clinical trials, were examined. Results/conclusions : Caution in the use of cefepime should be adopted until new evidence on cefepime safety is available.

show abstract

The Pharmacokinetics, Safety, and Tolerance of Cefepime Administered as an Intravenous Bolus or as a Rapid Infusion

Abstract: Cefepime 2 g was safely administered to healthy subjects as a rapid, single bolus, and its key pharmacokinetic parameters were consistent with those from longer infusions and other studies.

Cited by 28 publications

References 11 publications

Influence of E. coli lipopolysaccharide induced fever on the plasma kinetics of cefepime in cross-bred calves

Influence of E. coli lipopolysaccharide induced fever on the plasma kinetics of cefepime in cross-bred calves

Pharmacokinetic disposition and bioavailability of cefepime in buffalo calves

The safety of cefepime in the treatment of infection

Contact Info

Product

Resources

About